TL;DR
This study reveals that SARS-CoV-2 infection triggers a significant activation of the complement system, particularly within lung and liver cells, and this activation is linked to disease severity. Targeting the JAK1/2-STAT1 pathway with drugs like Ruxolitinib shows promise in mitigating this hyper-activation, suggesting a potential therapeutic strategy for COVID-19.
What Problem Does This Paper Address?
Despite the widespread impact of COVID-19, the precise molecular mechanisms driving its severe clinical manifestations remain incompletely understood. While the ACE2 receptor's role in viral entry is known, the downstream host pathways that lead to organ damage are less clear. This paper investigates the host response to SARS-CoV-2 infection, specifically focusing on the complement system, an integral part of innate immunity, and its potential role in the pathogenesis of COVID-19. The authors aim to identify key cellular pathways activated by the virus and explore potential therapeutic interventions targeting these pathways.
Methods
The researchers employed a multi-pronged approach:
- RNA-sequencing (RNA-seq): Bulk RNA-seq was used to compare gene expression profiles in lung tissues from SARS-CoV-2 infected patients versus healthy controls, as well as in various cell models (primary human bronchial epithelial cells, A549 cell lines, and ACE2-transduced A549 cells) infected with SARS-CoV-2.
- Gene Set Enrichment Analysis (GSEA): GSEA was a primary tool to identify significantly enriched biological pathways in the RNA-seq data, allowing for the comparison of gene expression patterns across different conditions and cell types.
- Single-cell RNA-sequencing (scRNA-seq): scRNA-seq data from bronchoalveolar lavage (BAL) samples of COVID-19 patients and healthy individuals was analyzed to understand cell-type-specific responses to SARS-CoV-2 infection.
- Transcription Factor (TF) Prediction and Pathway Analysis: Tools like Ingenuity Pathway Analysis (IPA) were used to predict key transcription factors regulating the observed gene expression changes.
- ChIP-sequencing (ChIP-seq): Publicly available ChIP-seq data for STAT1 and RELA, along with H3K27Ac (a marker of active chromatin), were analyzed to identify direct binding of these TFs to the promoters of SARS-CoV-2-induced genes.
- Pharmaceutical Drug Prediction: A drug signature database (DSigDB) was used to predict existing drugs that could normalize the SARS-CoV-2-induced gene expression signatures.
- In vitro experiments: The effects of Ruxolitinib, a JAK1/2 inhibitor, were tested on SARS-CoV-2 infected A549 cells to validate the drug prediction.
- Mouse models: Data from a ferret model of SARS-CoV infection was used to corroborate findings on complement gene transcription.
Datasets
- Publicly available RNA-seq data:
- Lung tissues from SARS-CoV-2 infected patients and healthy controls.
- Primary human bronchial epithelial (NHBE) cells infected with SARS-CoV-2.
- A549 alveolar cell lines infected with SARS-CoV-2.
- A549 cells transduced to express ACE2 and then infected with SARS-CoV-2.
- Ferret nasal washes from SARS-CoV-2 infected ferrets.
- Human hepatocyte cell line (Huh7) infected with SARS-CoV-2.
- Publicly available single-cell RNA-sequencing data:
- Bronchoalveolar lavage (BAL) samples from patients with mild and severe COVID-19, and lung biopsies from healthy individuals (GSE145926 and GSE122960).
- Publicly available ChIP-sequencing data:
- STAT1 and H3K27Ac ChIP-seq datasets from ENCODE.
- RELA ChIP-seq dataset from GSE132018.
- STAT1 wild-type and STAT1 knockout HepG2 liver cells treated with IFN-α (GSE98372).
Key Insights and Ideas
- Complement System as a Major Player: The complement system, traditionally viewed as a serum-based defense mechanism, is surprisingly and significantly activated intrinsically within lung epithelial and liver cells upon SARS-CoV-2 infection. This challenges the conventional understanding of complement's role.
- Cell-Type Specific Signatures: Complement activation signatures vary across different immune and epithelial cell types in the lungs, and these signatures correlate with disease severity. This highlights the complex cellular interplay in COVID-19 pathogenesis.
- JAK1/2-STAT1 Pathway is Central: The JAK1/2-STAT1 signaling pathway, downstream of type I interferon receptors, emerges as a critical regulator of host gene responses to SARS-CoV-2, including the induction of complement genes.
- Ruxolitinib's Therapeutic Potential: Ruxolitinib, a JAK1/2 inhibitor, effectively normalizes many SARS-CoV-2 induced genes, including key complement components and IL-6, a known severity marker. This suggests it could be a valuable therapeutic agent.
- NF-κB Pathway Remains a Challenge: While Ruxolitinib targets the JAK-STAT pathway, it does not fully normalize genes regulated by the NF-κB pathway, suggesting that a combination therapy might be necessary for optimal treatment.
- Local Complement Production: Respiratory epithelial cells appear to be a significant source of local complement production in lung tissues, especially where serum complement might be limited.
Key Results
- GSEA revealed that complement pathways were among the most highly enriched pathways in SARS-CoV-2 infected lung epithelial cells, liver cells, and patient BAL samples.
- In scRNA-seq analysis, C3 expression was significantly higher in AT2 cells of COVID-19 patients compared to healthy donors, indicating in vivo induction.
- CD46-regulated and C3aR-regulated gene expression tracked with disease severity in lymphoid and myeloid cells, respectively.
- IPA predicted that half of the top ten transcription factors regulating SARS-CoV-2 induced genes were IFN-pathway signaling proteins, including STAT1, and two were NF-κB family TFs, including RELA.
- ChIP-seq data showed significant enrichment for STAT1 and RELA binding at the promoter regions of key complement genes (C3, CFB, C1R, C1S) and IL-6.
- Ruxolitinib was predicted as the top candidate drug to normalize the SARS-CoV-2 gene signature in both NHBE and A549 cells.
- Experimental validation showed that Ruxolitinib treatment normalized the expression of IL-6, IRF7, IRF9, and all observed complement components in SARS-CoV-2 infected A549-ACE2 cells.
- Genes not normalized by Ruxolitinib were enriched for NF-κB signaling pathways.
Limitations and Future Work
- Off-target effects of JAK inhibitors: The authors acknowledge that JAK inhibitors can have off-target effects, and STAT3 could be activated by IL-6, necessitating efforts to attribute complement regulation directly to STAT1.
- Incomplete normalization by Ruxolitinib: Ruxolitinib did not fully normalize all SARS-CoV-2 induced genes, particularly those regulated by NF-κB. This suggests that monotherapy with JAK inhibitors might be insufficient.
- Future Work: The authors propose that combination therapy with JAK inhibitors and agents that modulate the NF-κB pathway (e.g., antivirals) could be a more effective clinical strategy. They also suggest that combining a JAKi with a second agent might allow for lower doses, potentially mitigating thrombotic risks associated with JAK inhibitors. The unexplored connections between complement activity and type I IFN responses during pathogen encounter are also highlighted as an area for future research.
Summary updated